Welcome Stockaholics!

We are a new and fast growing financial forum! Sign up for free and let's talk stocks!

  1. Do you want to help develop this community? We are looking for contributions from investors and traders like you! What stocks do you follow? What is hot right now? Sign up and get in on the ground floor of the newest, fastest growing financial forum!
    Dismiss Notice
  2. You will notice a live chat widget on the right. Click in to join us and lets hear about how you nailed that last UWTI trade!
    Dismiss Notice

TEVA - Teva Pharmaceuticals

Discussion in 'Stock Message Boards NYSE, NASDAQ, AMEX' started by T0rm3nted, May 10, 2016.

  1. T0rm3nted

    T0rm3nted Moderator
    Staff Member

    Joined:
    Apr 2, 2016
    Messages:
    6,677
    Likes Received:
    1,798
    [​IMG]
    Teva Pharmaceutical Industries Ltd. (TEVA) is an Israeli-American multinational pharmaceutical company headquartered in Petah Tikva, Israel. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and to a lesser extent proprietary pharmaceuticals. It is the largest generic drug manufacturer in the world and one of the 15 largest pharmaceutical companies worldwide. Teva's facilities are located in Israel, North America, Europe, and South America. Teva is a member of both the New York Stock Exchange and the Tel Aviv Stock Exchange.
     
  2. T0rm3nted

    T0rm3nted Moderator
    Staff Member

    Joined:
    Apr 2, 2016
    Messages:
    6,677
    Likes Received:
    1,798
    Reported before open today (5/9/16)
    Earnings: EPS $1.36 Revenue $4.9B
    Estimates: EPS $1.18 Revenue $4.9B

    Up 5.05% today
     
  3. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    6,658
    Likes Received:
    1,791
    New lows again!
     
  4. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    6,658
    Likes Received:
    1,791
    News Of Clinical Hold For Fasinumab Weighs On Regeneron, Teva Shares

    Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Teva Pharmaceuticals Ltd (ADR) (NYSE: TEVA) came under selling pressure after the FDA placed the second stage study on chronic low back pain on hold. The companies are involved in developing fasinumab for treating low back pain.

    The drug candidate is an investigational Nerve Growth Factor antibody in clinical development for osteoarthritis pain and low back pain. The FDA advised to hold the study and make amendments to the trial protocol following its observation of a case adjudicating arthropathy in a patient, who got high dosage of fasinumab. The patient had an advanced osteoarthritis at trial entry.

    Following the regulator's decision, Regeneron indicated it completed an unplanned interim review of results. The company also stopped dosing in the trial. The company indicated that its unplanned analysis demonstrated evidence of efficacy with improvement in pain scores compared to placebo involving a period of 8 and 12 weeks
     
  5. T0rm3nted

    T0rm3nted Moderator
    Staff Member

    Joined:
    Apr 2, 2016
    Messages:
    6,677
    Likes Received:
    1,798
    Analyst Upgrade/Downgrade Update

    Brokerage firm:
    Mizuho
    Change: Downgrade
    Previous Rating: Buy
    Current Rating: Neutral
    Previous Price Target: $64
    Current Price Target: $45
     
  6. T0rm3nted

    T0rm3nted Moderator
    Staff Member

    Joined:
    Apr 2, 2016
    Messages:
    6,677
    Likes Received:
    1,798
    Analyst Upgrade/Downgrade Update

    Brokerage firm:
    RBC Capital Mkts
    Change: Coverage Reiterated/Price Target Changed
    Previous Rating: N/A
    Current Rating: Outperform
    Previous Price Target: $71
    Current Price Target: $58
     
  7. T0rm3nted

    T0rm3nted Moderator
    Staff Member

    Joined:
    Apr 2, 2016
    Messages:
    6,677
    Likes Received:
    1,798
    Reported before open today (11/15/16)

    Earnings: EPS $1.31 Revenue $5.56B
    Estimates: EPS $1.29 Revenue $5.75B

    Down 8.36% today
     
  8. T0rm3nted

    T0rm3nted Moderator
    Staff Member

    Joined:
    Apr 2, 2016
    Messages:
    6,677
    Likes Received:
    1,798
    Analyst Upgrade/Downgrade Update

    Brokerage firm: Morgan Stanley
    Change: Downgrade
    Previous Rating: Overweight
    Current Rating: Equal Weight
    Previous Price Target: N/A
    Current Price Target: N/A

    Analyst Upgrade/Downgrade Update

    Brokerage firm: Jefferies
    Change: Downgrade
    Previous Rating: Buy
    Current Rating: Hold
    Previous Price Target: $69
    Current Price Target: $40
     
    #8 T0rm3nted, Nov 16, 2016
    Last edited: Nov 16, 2016
  9. T0rm3nted

    T0rm3nted Moderator
    Staff Member

    Joined:
    Apr 2, 2016
    Messages:
    6,677
    Likes Received:
    1,798
    Analyst Upgrade/Downgrade Update

    Brokerage firm:
    Deutsche Bank
    Change: Coverage Reiterated/Price Target Changed
    Previous Rating: N/A
    Current Rating: Buy
    Previous Price Target: $68
    Current Price Target: $54

    Analyst Upgrade/Downgrade Update

    Brokerage firm:
    Maxim Group
    Change: Coverage Reiterated/Price Target Changed
    Previous Rating: N/A
    Current Rating: Buy
    Previous Price Target: $72
    Current Price Target: $52

    Analyst Upgrade/Downgrade Update

    Brokerage firm:
    RBC Capital Mkts
    Change: Coverage Reiterated/Price Target Changed
    Previous Rating: N/A
    Current Rating: Outperform
    Previous Price Target: $58
    Current Price Target: $51

    Analyst Upgrade/Downgrade Update

    Brokerage firm:
    Mizuho
    Change: Coverage Reiterated/Price Target Changed
    Previous Rating: N/A
    Current Rating: Neutral
    Previous Price Target: $45
    Current Price Target: $40
     
  10. T0rm3nted

    T0rm3nted Moderator
    Staff Member

    Joined:
    Apr 2, 2016
    Messages:
    6,677
    Likes Received:
    1,798
    Upcoming Dividend Information:

    upload_2016-11-29_0-31-10.png
    upload_2016-11-29_0-31-24.png
     
  11. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    6,658
    Likes Received:
    1,791
    Holy crap this chart is getting uglier and uglier for longs.

    Put holders, not so bad!
     
  12. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    6,658
    Likes Received:
    1,791
    Im confused, the news today looks ok:

    JERUSALEM--(BUSINESS WIRE)--

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) today announced that it has received a positive outcome through the variation procedure to remove the pregnancy contraindication from the European label for COPAXONE® (glatiramer acetate injection) 20 mg/mL. The product was originally authorized through a decentralized procedure in Europe.
     
  13. fidelgeorge

    fidelgeorge Well-Known Member

    Joined:
    Apr 15, 2016
    Messages:
    971
    Likes Received:
    393
    This is the go to company for generics - isn't this what the new healthcare wants - inexpensive drugs to replace expensive brands.
     
  14. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    6,658
    Likes Received:
    1,791
    Some bounce action this morning, but I need to see +$35 to consider a change in trend.
     
  15. Gambit

    Gambit Active Member

    Joined:
    Oct 16, 2016
    Messages:
    705
    Likes Received:
    62
    $TEVA TEVA sell on good ##. TEVA is in steady downtrend, since last Dec it's being consolidating blw previous strong su Bearish
    [​IMG]
     
  16. Russell

    Russell New Member

    Joined:
    Apr 5, 2017
    Messages:
    2
    Likes Received:
    0
    TEVA is way undervalued. Future EPS puts its value more than double current share price. Financials are good, sentiment is bad. TEVA is currently one of the top 3 picks at wayundervalued.com

    I'll hold TEVA patiently, it could really pay off in the long term. Enjoy the 4% dividend in the meantime. When sentiment changes, there's lots of upside here. If expected EPS rises further, watch out..
     
  17. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    6,658
    Likes Received:
    1,791
    It has not been a pretty longer term chart so far this year, but waiting to see if this finds a bottom soon
     
  18. Gambit

    Gambit Active Member

    Joined:
    Oct 16, 2016
    Messages:
    705
    Likes Received:
    62
    TEVA slammed 15% after cutting outlook. U.S. growth slowing. Only major support I see is $22.85 from yrs ago.
     
  19. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    6,658
    Likes Received:
    1,791
    After 5 days of selling, I think this is going to get ripe soon.

    Watching for a bounce!
     
  20. fireopal

    fireopal Well-Known Member

    Joined:
    Apr 18, 2016
    Messages:
    2,508
    Likes Received:
    558
    #20 fireopal, Aug 16, 2017
    Last edited: Aug 16, 2017

Share This Page